Thomas Machnig

1.2k total citations
37 papers, 626 citations indexed

About

Thomas Machnig is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Thomas Machnig has authored 37 papers receiving a total of 626 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Genetics, 18 papers in Hematology and 9 papers in Rheumatology. Recurrent topics in Thomas Machnig's work include Coagulation, Bradykinin, Polyphosphates, and Angioedema (35 papers), Hemophilia Treatment and Research (17 papers) and Mast cells and histamine (9 papers). Thomas Machnig is often cited by papers focused on Coagulation, Bradykinin, Polyphosphates, and Angioedema (35 papers), Hemophilia Treatment and Research (17 papers) and Mast cells and histamine (9 papers). Thomas Machnig collaborates with scholars based in United States, Germany and United Kingdom. Thomas Machnig's co-authors include Timothy Craig, Konrad Bork, Jonathan A. Bernstein, Mikhail Rojavin, Richard L. Wasserman, K. Wulff, Guenther Witzke, Jochen Hardt, Kraig W. Jacobson and Againdra K. Bewtra and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Allergy and Transfusion.

In The Last Decade

Thomas Machnig

34 papers receiving 605 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Machnig United States	15	582	225	195	183	182	37	626
Henrik Balle Boysen United States	10	664 1.1×	273 1.2×	196 1.0×	170 0.9×	228 1.3×	12	717
Guenther Witzke Germany	8	458 0.8×	180 0.8×	115 0.6×	159 0.9×	189 1.0×	10	490
Beáta Visy Hungary	10	563 1.0×	235 1.0×	175 0.9×	214 1.2×	209 1.1×	22	604
Nóra Veszeli Hungary	14	355 0.6×	141 0.6×	147 0.8×	85 0.5×	107 0.6×	35	466
Vesna Grivcheva‐Panovska North Macedonia	8	402 0.7×	168 0.7×	136 0.7×	127 0.7×	116 0.6×	16	427
M. Baş Germany	5	448 0.8×	226 1.0×	99 0.5×	129 0.7×	175 1.0×	7	476
György Temesszentandrási Hungary	8	325 0.6×	132 0.6×	113 0.6×	103 0.6×	91 0.5×	11	375
L. Bouillet France	9	611 1.0×	285 1.3×	181 0.9×	168 0.9×	241 1.3×	17	652
Romualdo Vacchini Italy	7	330 0.6×	174 0.8×	74 0.4×	68 0.4×	134 0.7×	8	349
Donald McNeil United States	4	335 0.6×	153 0.7×	108 0.6×	89 0.5×	121 0.7×	14	415

Countries citing papers authored by Thomas Machnig

Since Specialization

Citations

This map shows the geographic impact of Thomas Machnig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Machnig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Machnig more than expected).

Fields of papers citing papers by Thomas Machnig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Machnig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Machnig. The network helps show where Thomas Machnig may publish in the future.

Co-authorship network of co-authors of Thomas Machnig

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Machnig. A scholar is included among the top collaborators of Thomas Machnig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Machnig. Thomas Machnig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lumry, William R., Bruce L. Zuraw, Marco Cicardi, et al.. (2021). Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases. 16(1). 329–329. 24 indexed citations

Bork, Konrad, et al.. (2020). Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence. Orphanet Journal of Rare Diseases. 15(1). 289–289. 67 indexed citations

Bork, Konrad, K. Wulff, Guenther Witzke, Thomas Machnig, & Jochen Hardt. (2020). Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene. Orphanet Journal of Rare Diseases. 15(1). 52–52. 23 indexed citations

Bernstein, Jonathan A., Timothy Craig, Michael Manning, et al.. (2019). Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks. Allergy Asthma and Clinical Immunology. 15(1). 13–13. 13 indexed citations

Li, H. Henry, Bruce L. Zuraw, Hilary Longhurst, et al.. (2019). Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study. Allergy Asthma and Clinical Immunology. 15(1). 49–49. 9 indexed citations

Watson, Douglas J., Marc A. Riedl, Aleena Banerji, et al.. (2018). Use Of Central Venous Access Devices (CVAD) And Associated Outcomes In Hereditary Angioedema (HAE) Patients: Findings From A Large United States (US) Claims Database. Journal of Allergy and Clinical Immunology. 141(2). AB50–AB50. 1 indexed citations

Lumry, William R., Timothy Craig, Bruce L. Zuraw, et al.. (2018). Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema. The Journal of Allergy and Clinical Immunology In Practice. 6(5). 1733–1741.e3. 67 indexed citations

Riedl, Marc A., Aleena Banerji, Michael Manning, et al.. (2018). Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States. Orphanet Journal of Rare Diseases. 13(1). 180–180. 15 indexed citations

Zhang, Ying, Michael A. Tortorici, Dipti Pawaskar, et al.. (2018). Exposure‐Response Model of Subcutaneous C1‐Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema. CPT Pharmacometrics & Systems Pharmacology. 7(3). 158–165. 12 indexed citations

10.

Riedl, Marc A., Aleena Banerji, Michael Manning, et al.. (2017). Intravenous C1-INH [C1-INH(IV)] Use Among Patients with Hereditary Angioedema (HAE) in the United States (US) and Associated Health Care Resource Utilization (HCRU). Journal of Allergy and Clinical Immunology. 139(2). AB231–AB231.

11.

Riedl, Marc A., Aleena Banerji, Paula J. Busse, et al.. (2017). Patient satisfaction and experience with intravenously administered C1-inhibitor concentrates in the United States. Annals of Allergy Asthma & Immunology. 119(1). 59–64. 28 indexed citations

12.

Farkas, Henriette, Lilian Varga, Dumitru Moldovan, et al.. (2016). Assessment of inhibitory antibodies in patients with hereditary angioedema treated with plasma-derived C1 inhibitor. Annals of Allergy Asthma & Immunology. 117(5). 508–513. 6 indexed citations

13.

Bork, Konrad, Jonathan A. Bernstein, Thomas Machnig, & Timothy Craig. (2016). Efficacy of Different Medical Therapies for the Treatment of Acute Laryngeal Attacks of Hereditary Angioedema due to C1-esterase Inhibitor Deficiency. Journal of Emergency Medicine. 50(4). 567–580.e1. 14 indexed citations

14.

Busse, Paula J., Anette Bygum, Jonathan M. Edelman, et al.. (2014). Safety of C1-Esterase Inhibitor in Acute and Prophylactic Therapy of Hereditary Angioedema: Findings from the Ongoing International Berinert Patient Registry. The Journal of Allergy and Clinical Immunology In Practice. 3(2). 213–219. 23 indexed citations

15.

Craig, Timothy, et al.. (2013). Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks. Annals of Allergy Asthma & Immunology. 111(3). 211–215. 39 indexed citations

16.

Bewtra, Againdra K., Robyn J. Levy, Richard L. Wasserman, et al.. (2012). Per-Attack Reporting of Prodromal Symptoms Concurrent with C1-Inhibitor Treatment of Hereditary Angioedema Attacks. Advances in Therapy. 29(10). 913–922. 24 indexed citations

17.

Schneider, Lynda C., David Hurewitz, Richard L. Wasserman, et al.. (2012). C1‐INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. studies. Pediatric Allergy and Immunology. 24(1). 54–60. 29 indexed citations

18.

Craig, Timothy, Againdra K. Bewtra, Sami L. Bahna, et al.. (2011). C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks - final results of the I.M.P.A.C.T.2 study. Allergy. 66(12). 1604–1611. 104 indexed citations

19.

Machnig, Thomas, Apostolos Koroneos, K. Bachmann, et al.. (1994). [Quantitative evaluation of myocardial perfusion with ultrafast magnetic resonance tomography].. PubMed. 83(11). 840–50. 2 indexed citations

20.

Machnig, Thomas, et al.. (1990). Bestimmung von Parametern der Myokardperfusion aus Koronarangiogrammen durch Analyse der myokardialen Kontrastmittelpassage. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 153(9). 252–259.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact